We are live on ! Find out more
ORIC icon

Oric Pharmaceuticals
ORIC

82 hedge funds and large institutions have $762M invested in Oric Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 34 increasing their positions, 20 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 20

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

19% more capital invested

Capital invested by funds: $639M → $762M (+$123M)

5% more funds holding

Funds holding: 78 → 82 (+4)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

5.86% less ownership

Funds ownership: 98.49% → 92.63% (-5.9%)

Holders
82
Holders Change
+4
Holders Change %
+5.13%
% of All Funds
1.44%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
10
Increased
34
Reduced
20
Closed
6
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
–

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.97M
2
EC
EcoR1 Capital
California
+$7.64M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$7.4M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.93M
5
Victory Capital Management
Victory Capital Management
Texas
+$4.9M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$12.4M
2
RCM
RA Capital Management
Massachusetts
-$10.3M
3
EC
Euclidean Capital
New York
-$4.45M
4
Millennium Management
Millennium Management
New York
-$4.1M
5
State Street
State Street
Massachusetts
-$3.89M
Name Holding Trade Value Shares
Change 		Change in
Stake
VOYA Investment Management
26
VOYA Investment Management
Georgia
$3.84M +$617K +30,461 +20%
SCM
27
Suvretta Capital Management
New York
$3.12M +$3.02M +149,100 New
N
28
Nuveen
North Carolina
$3.01M +$81.5K +4,019 +3%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$2.32M +$588K +28,995 +35%
Alyeska Investment Group
30
Alyeska Investment Group
Illinois
$2.3M -$3.55M -175,000 -61%
PPA
31
Parametric Portfolio Associates
Washington
$1.17M +$417K +20,574 +58%
IBT
32
International Biotechnology Trust
United Kingdom
$1.1M – – –
Swiss National Bank
33
Swiss National Bank
Switzerland
$1.1M – – –
LCM
34
Laurion Capital Management
New York
$1M -$267K -13,155 -22%
Goldman Sachs
35
Goldman Sachs
New York
$845K +$136K +6,718 +20%
State of Wisconsin Investment Board
36
State of Wisconsin Investment Board
Wisconsin
$799K +$40.4K +1,995 +6%
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$762K -$86K -4,242 -10%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$760K +$52.3K +2,578 +8%
Prudential Financial
39
Prudential Financial
New Jersey
$741K +$7.7K +380 +1%
Rafferty Asset Management
40
Rafferty Asset Management
New York
$655K -$331K -16,323 -34%
AllianceBernstein
41
AllianceBernstein
Tennessee
$592K – – –
Citigroup
42
Citigroup
New York
$556K -$1.17M -57,876 -69%
UBS Group
43
UBS Group
Switzerland
$544K +$380K +18,747 +259%
SG Americas Securities
44
SG Americas Securities
New York
$528K +$512K +25,235 New
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$496K -$72.7K -3,585 -13%
JP Morgan Chase
46
JP Morgan Chase
New York
$459K +$112K +5,505 +33%
Deutsche Bank
47
Deutsche Bank
Germany
$458K +$34.3K +1,692 +8%
SFI
48
Susquehanna Fundamental Investments
Pennsylvania
$447K +$434K +21,399 New
Los Angeles Capital Management
49
Los Angeles Capital Management
California
$426K -$30.8K -1,520 -7%
Morgan Stanley
50
Morgan Stanley
New York
$396K -$2.58M -127,101 -87%
1
2
3 4

ORIC Hedge Fund Activity: Q3 2021 in Review

82 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q3 2021, worth a combined $762M — up 19% from $639M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ORIC positions and 6 closed out — a net gain of 4 holders — while 34 added to existing stakes and 20 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $7.97M. The largest seller was Point72 Asset Management, cutting an estimated $12.4M.

  • 82 institutional investors held Oric Pharmaceuticals (ORIC) as of Q3 2021, up from 78 in Q2 2021.
  • Funds reported $762M of Oric Pharmaceuticals stock for Q3 2021, up 19% quarter-over-quarter.
  • 10 funds opened new Oric Pharmaceuticals positions in Q3 2021 and 6 closed out, a net change of +4 holders.
  • The largest Oric Pharmaceuticals buyer in Q3 2021 was Fidelity Investments, an estimated $7.97M added.
  • The largest Oric Pharmaceuticals seller in Q3 2021 was Point72 Asset Management, an estimated $12.4M sold.

Based on aggregated 13F filings for Q3 2021.